Format
Sort by
Items per page

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 112

1.

Reduced cellularity of bone marrow in multiple sclerosis with decreased MSC expansion potential and premature ageing in vitro.

Redondo J, Sarkar P, Kemp K, Virgo PF, Pawade J, Norton A, Emery DC, Guttridge MG, Marks DI, Wilkins A, Scolding NJ, Rice CM.

Mult Scler. 2017 May 1:1352458517711276. doi: 10.1177/1352458517711276. [Epub ahead of print]

PMID:
28548004
2.

Cell Therapy for Multiple Sclerosis.

Sarkar P, Rice CM, Scolding NJ.

CNS Drugs. 2017 Apr 10. doi: 10.1007/s40263-017-0429-9. [Epub ahead of print] Review.

PMID:
28397112
3.

Cytokine therapy-mediated neuroprotection in a Friedreich's ataxia mouse model.

Kemp KC, Cerminara N, Hares K, Redondo J, Cook AJ, Haynes HR, Burton BR, Pook M, Apps R, Scolding NJ, Wilkins A.

Ann Neurol. 2017 Feb;81(2):212-226. doi: 10.1002/ana.24846.

4.

Neurosarcoidosis: a clinical approach to diagnosis and management.

Ibitoye RT, Wilkins A, Scolding NJ.

J Neurol. 2017 May;264(5):1023-1028. doi: 10.1007/s00415-016-8336-4. Epub 2016 Nov 22.

5.

Percutaneous Endoscopic Gastrostomy Tube Insertion in Neurodegenerative Disease: A Retrospective Study and Literature Review.

Sarkar P, Cole A, Scolding NJ, Rice CM.

Clin Endosc. 2016 Oct 13. doi: 10.5946/ce.2016.106. [Epub ahead of print]

6.

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.

Giovannoni G, Cohen JA, Coles AJ, Hartung HP, Havrdova E, Selmaj KW, Margolin DH, Lake SL, Kaup SM, Panzara MA, Compston DA; CARE-MS II Investigators..

Neurology. 2016 Nov 8;87(19):1985-1992. Epub 2016 Oct 12.

7.

Erdheim-Chester disease: 25-year history with early CNS involvement.

Rice CM, Hall CA, McCoubrie P, Renowden SA, Cohen N, Scolding NJ.

BMJ Case Rep. 2016 Oct 4;2016. pii: bcr2016216747. doi: 10.1136/bcr-2016-216747.

PMID:
27702933
8.

Ovarioleukodystrophy due to EIF2B5 mutations.

Ibitoye RT, Renowden SA, Faulkner HJ, Scolding NJ, Rice CM.

Pract Neurol. 2016 Dec;16(6):496-499. doi: 10.1136/practneurol-2016-001382. Epub 2016 Sep 20.

PMID:
27651498
9.

Erratum to: 'Purkinje cell injury, structural plasticity and fusion in patients with Friedreich's ataxia'.

Kemp KC, Cook AJ, Redondo J, Kurian KM, Scolding NJ, Wilkins A.

Acta Neuropathol Commun. 2016 Jun 30;4(1):67. No abstract available.

10.

Purkinje cell injury, structural plasticity and fusion in patients with Friedreich's ataxia.

Kemp KC, Cook AJ, Redondo J, Kurian KM, Scolding NJ, Wilkins A.

Acta Neuropathol Commun. 2016 May 23;4(1):53. doi: 10.1186/s40478-016-0326-3. Erratum in: Acta Neuropathol Commun. 2016;4(1):67.

11.

Intracranial spread of IgG4-related disease via skull base foramina.

Rice CM, Spencer T, Bunea G, Scolding NJ, Sloan P, Nath U.

Pract Neurol. 2016 Jun;16(3):240-2. doi: 10.1136/practneurol-2015-001315. Epub 2016 Feb 8.

PMID:
26856357
12.

Tumefactive demyelination presenting during bevacizumab treatment.

Rice CM, Rossiter D, Fehmi J, Stevens JC, Renowden SA, Cohen N, Bailey C, Scolding NJ.

BMJ Case Rep. 2015 Dec 16;2015. pii: bcr2015212173. doi: 10.1136/bcr-2015-212173.

PMID:
26677151
13.

Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort.

Willis MD, Harding KE, Pickersgill TP, Wardle M, Pearson OR, Scolding NJ, Smee J, Robertson NP.

Mult Scler. 2016 Aug;22(9):1215-23. doi: 10.1177/1352458515614092. Epub 2015 Oct 29.

PMID:
26514979
14.

Assessment of bone marrow-derived Cellular Therapy in progressive Multiple Sclerosis (ACTiMuS): study protocol for a randomised controlled trial.

Rice CM, Marks DI, Ben-Shlomo Y, Evangelou N, Morgan PS, Metcalfe C, Walsh P, Kane NM, Guttridge MG, Miflin G, Blackmore S, Sarkar P, Redondo J, Owen D, Cottrell DA, Wilkins A, Scolding NJ.

Trials. 2015 Oct 14;16:463. doi: 10.1186/s13063-015-0953-1.

15.

Repeat infusion of autologous bone marrow cells in multiple sclerosis: protocol for a phase I extension study (SIAMMS-II).

Rice CM, Marks DI, Walsh P, Kane NM, Guttridge MG, Redondo J, Sarkar P, Owen D, Wilkins A, Scolding NJ.

BMJ Open. 2015 Sep 11;5(9):e009090. doi: 10.1136/bmjopen-2015-009090.

16.

Idiopathic hypereosinophilic syndrome: a new cause of vasculitis of the central nervous system.

Rice CM, Kurian KM, Renowden S, Whiteway A, Price C, Scolding NJ.

J Neurol. 2015 May;262(5):1354-9. doi: 10.1007/s00415-015-7720-9. Epub 2015 Apr 7.

PMID:
25843450
17.

Preclinical development and first-in-human study of ATX-MS-1467 for immunotherapy of MS.

Streeter HB, Rigden R, Martin KF, Scolding NJ, Wraith DC.

Neurol Neuroimmunol Neuroinflamm. 2015 Mar 12;2(3):e93. doi: 10.1212/NXI.0000000000000093. eCollection 2015 Jun.

18.

Immune reconstitution and treatment response in multiple sclerosis following alemtuzumab.

Robertson NP, Scolding NJ.

Neurology. 2014 Jun 17;82(24):2150-1. doi: 10.1212/WNL.0000000000000530. Epub 2014 May 16. No abstract available.

PMID:
24838787
19.

Cell therapy for multiple sclerosis: an evolving concept with implications for other neurodegenerative diseases.

Rice CM, Kemp K, Wilkins A, Scolding NJ.

Lancet. 2013 Oct 5;382(9899):1204-13. doi: 10.1016/S0140-6736(13)61810-3.

PMID:
24095194
20.

Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial.

Zajicek J, Ball S, Wright D, Vickery J, Nunn A, Miller D, Gomez Cano M, McManus D, Mallik S, Hobart J; CUPID investigator group..

Lancet Neurol. 2013 Sep;12(9):857-65. doi: 10.1016/S1474-4422(13)70159-5. Epub 2013 Jul 13. Review.

Supplemental Content

Loading ...
Support Center